How to use vancomycin optimally in neonates: Remaining questions

Expert Review of Clinical Pharmacology

Volumn 8, Issue 5, 2015, Pages 635-648

  Jacqz Aigrain, Evelyne ^a,b   Leroux, Stephanie ^a,c   Zhao, Wei ^a,b,c   Van Den Anker, John N ^d,e,f   Sharland, Mike ^g  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

^d CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^e UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^f SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^g ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Continuous infusion; Dosing optimization; Formulation; Modeling and simulation; Neonates; Nephrotoxicity; Ototoxicity; Pharmacokinetics; Therapeutic drug monitoring; Vancomycin

Indexed keywords

VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; CLINICAL TRIAL (TOPIC); DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INFUSION; DRUG INTERMITTENT THERAPY; DRUG MONITORING; DRUG SAFETY; DRUG USE; HISTORY OF MEDICINE; HUMAN; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NEONATOLOGIST; NEWBORN; NEWBORN CARE; NEWBORN INTENSIVE CARE; NEWBORN SEPSIS; REVIEW; TREATMENT DURATION; VOLUME OF DISTRIBUTION; AGONISTS; COMPUTER SIMULATION; DOSE RESPONSE; GRAM POSITIVE INFECTION; PROCEDURES; SEPSIS;

ANTI-BACTERIAL AGENTS; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INFANT, NEWBORN; INTENSIVE CARE UNITS, NEONATAL; SEPSIS; VANCOMYCIN;

EID: 84940614677     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2015.1060124     Document Type: Review

References (107)

1. Cohen-Wolkowiez M, Moran C, Benjamin DK, et al. Early and late onset sepsis in late preterm infants. Pediatr Infect Dis J 2009; 28: 1052e7
2. Stoll BJ, Gordon T, Korones SB, et al. Late-onset sepsis in very low birth weight neonates: A report from the National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr 1996; 129: 63e71
3. Stoll BJ, Hansen N, Fanaroff AA, et al. Changes in pathogens causing early-onset sepsis in very-low-birth-weight infants. N Engl J Med 2002; 347: 240e7
4. Jacqz-Aigrain E, Zhao W, Sharland M, van den Anker JN. Use of antibacterial agents in the neonate: 50 years of experience with vancomycin administration. Semin Fetal Neonatal Med 2013; 18: 28-34
5. Revised priority list for studies into off-patent paediatric medicinal products (EMA/98717/2012). European Medicines Agency, London, UK. Available from: http: //www. ema. europa. eu/docs/en-GB/ document-library/Other/2009/10/ WC500004017. pdf
6. Dawson PM. Vancomycin and gentamicin in neonates: hindsight, current controversies, and forethought. J Perinat Neonatal Nurs 2002; 16: 54-72
7. Rubin LG, Sánchez PJ, Siegel J, et al. Pediatric Prevention Network. Evaluation and treatment of neonates with suspected late-onset sepsis: A survey of neonatologists' practices. Pediatrics 2002; 110: e42
8. Sun H, Maderazo EG, Krusell AR. Serum protein-binding characteristics of vancomycin. Antimicrob Agents Chemother 1993; 37: 1132-6
9. Lundstrom TS, Sobel JD. Antibiotics for gram-positive bacterial infections: vancomycin, quinupristin-dalfopristin, linezolid, and daptomycin. Infect Dis Clin North Am 2004; 18: 651-68
10. Rybak MJ, Albrecht LM, Berman JR, et al. Vancomycin pharmacokinetics in burn patients and intravenous drug abusers. Antimicrob Agents Chemother 1990; 34: 792-5
11. Golper TA, Noonan HM, Elzinga L, et al. Vancomycin pharmacokinetics, renal handling, and non renal clearances in normal human subjects. Clin Pharmacol Ther 1988; 43: 565-70
12. de Hoog M, Mouton JW, van den Anker JN. Vancomycin: Pharmacokinetics and administration regimens in neonates. Clin Pharmacokinet 2004; 43: 417-40
13. Marsot A, Boulamery A, Bruguerolle B, Simon N. Vancomycin: A review of population pharmacokinetic analyses. Clin Pharmacokinet 2012; 51: 1-13
14. Brendel K, Dartois C, Comets E, et al. Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin Pharmacokinet 2007; 46: 221-34
15. Allegaert K, Anderson BJ, van den Anker JN, et al. Renal drug clearance in preterm neonates: relation to prenatal growth. Ther Drug Monit 2007; 29: 284-91
16. Kimura T, Sunakawa K, Matsuura N, et al. Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates. Antimicrob Agents Chemother 2004; 48: 1159-67
17. Lo YL, van Hasselt JG, Heng SC, et al. Population pharmacokinetics of vancomycin in premature Malaysian neonates: identification of predictors for dosing determination. Antimicrob Agents Chemother 2010; 54: 2626-32
18. Marques-Miñana MR, Saadeddin A, Peris JE. Population pharmacokinetic analysis of vancomycin in neonates. A new proposal of initial dosage guideline. Br J Clin Pharmacol 2010; 70: 713-20
19. Grimsley C, Thomson AH. Pharmacokinetics and dose requirements of vancomycin in neonates. Arch Dis Child Fetal Neonatal Ed 1999; 81: F221-7
20. Capparelli EV, Lane JR, Romanowski GL, et al. The influences of renal function and maturation on vancomycin elimination in newborns and infants. J Clin Pharmacol 2001; 41: 927-34
21. Zhao W, Kaguelidou F, Biran V, et al. External evaluation of population pharmacokinetic models of vancomycin in neonates: the transferability of published models to different clinical settings. Br J Clin Pharmacol 2013; 75(4): 1068-80
22. Leroux S, Zhao W, Betremieux P, et al. Therapeutic guidelines for prescribing antibiotics in neonates should be evidencebased: A French national survey. ADC 2015; doi: 10. 1136/archdischild-2014-306873
23. van den Anker JN. Renal function in preterm infants. Eur J Pediatr 1997; 156: 583-4
24. Peake M, Whiting M. Measurement of serum creatinine-current status and future goals. Clin Biochem Rev 2006; 27: 173-84
25. Anne L, Hu M, Chan K, et al. Potential problem with fluorescence polarization immunoassay cross-reactivity to vancomycin degradation product CDP-1: its detection in sera of renally impaired patients. Ther Drug Monit 1989; 11: 585-91
26. Smith PF, Morse GD. Accuracy of measured vancomycin serum concentrations in patients with end-stage renal disease. Ann Pharmacother 1999; 33: 1329-35
27. Legatt DF, Blakney GB, Higgins TN, et al. The effect of paraproteins and rheumatoid factor on four commercial immunoassays for vancomycin: implications for laboratorians and other health care professionals. Ther Drug Monit 2012; 34: 306-11
28. Zhao W, Jacqz-Aigrain E. The importance of knowing how vancomycin is measured when interpreting its pharmacokinetic results. Ther Drug Monit 2013; 35: 416
29. EMA. Note for guidance on evaluation of medicinal products indicated for treatment of bacterial infections (CPMP/EWP/558/ 95 rev 1). Available from: http: //www. ema. europa. eu/docs/en-GB/document-library/ Scientific-guideline/2009/09/ WC500003417. pdf
30. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphyloccocus Aureus lower respiratory tract infection. Clin Pharmacokinet 2004; 43: 925-42
31. Rubak MJ, Lomaestro BM, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adults: summary of consessus from the american society of health-ssystem pharmacists, the infectiuos diseases society of america and the society of infectious diseases pharmacists. Pharmacotherapy 2009; 28: 1275-9
32. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004; 43(13): 925-42
33. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the american society of health-system pharmacists, the infectious diseases society of america, and the society of infectious diseases pharmacists. Pharmacotherapy 2009; 29: 1275-9
34. Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42: 2398-402
35. EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance-Version 1. 0-October 2013. Available from: www. eucast. org January 2015
36. Ho PL, Lo PY, Chow KH, et al. Vancomycin MIC creep in MRSA isolates from 1997 to 2008 in a healthcare region in Hong Kong. J Infect 2010; 60: 140-5
37. Moise P, Sakoulas G, Forrest A, et al. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteraemia. Antimicrob Agents Chemother 2007; 51: 2582-6
38. Soriano A, Marco F, Martinez J, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin resistant Staphylococcus aureus bacteraemia. Clin Infect Dis 2008; 46: 193-200
39. The antimicrobial KnowledgeBase. Available from: www. Antibiotics. Toku-e. com
40. Mohr JF, Murray BE. Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2007; 44: 1536-42
41. Frymoyer A, Hersh AL, Coralic Z, et al. Prediction of vancomycin pharmacodynamics in children with invasive methicillin-resistant Staphylococcus aureus infections: A Monte Carlo simulation. Clin Ther 2010; 32: 534-42
42. Klingenberg C, Aarag E, Rønnestad A, et al. Coagulase-negative staphylococcal sepsis in neonates. Association between antibiotic resistance, biofilm formation and the host inflammatory response. Pediatr Infect Dis J 2005; 24: 817-22
43. Marchant EA, Boyce GK, Sadarangani M, Lavoie PM. Neoatal sepsis due to coagulase-negative staphylococci. Clin Dev Immunol 2013; 2013: 586076
44. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nature Immunol 2010; 11: 373-84
45. Baquero F, Coque TM, Canton R. Counteracting antibiotic resistance: breaking barriers among antibacterial strategies. Expert Opin Ther Targets 2014; 18: 851-61
46. Canton R, Morosini M. Emergence and spread of antibiotic resistance following exposure to antibiotics. FEMS Microbiol Rev 2011; 35: 977-91
47. Rodvold KA, Gentry CA, Plank GS, et al. Bayesian forecasting of serum vancomycin concentrations in neonates and infants. Ther Drug Monit 1995; 17: 239-46
48. Elyasi S, Khalili H, Dashti-Khavidaki S, Mohammadpour A. Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol 2012; 68: 1243-55
49. Bailie GR, Neal D. Vancomycin ototoxicity and nephrotoxicity. A review. Med Toxicol Adverse Drug Exp 1988; 3: 376-86
50. McKamy S, Hernandez E, Jahng M, et al. Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. J Pediatr 2011; 158: 422-6
51. Odio C, McCracken GH Jr, Nelson JD. Nephrotoxicity associated with vancomycin-aminoglycoside therapy in four children. J Pediatr 1984; 105: 491-3
52. Goren MP, Baker DK Jr, Shenep JL. Vancomycin does not enhance amikacin-induced tubular nephrotoxicity in children. Pediatr Infect Dis J 1989; 8: 278-82
53. Linder N, Edwards R, MeClead R, et al. Safety of vancomycin with or without gentamicin in neonates. Neonatal Netw 1993; 12: 27-30
54. Schreuder MF, Bueters RR, Allegaert K. The interplay between drugs and the kidney in premature neonates. Pediatr Nephrol 2014; 29: 2083-91
55. Schaad UB, Nelson JD, McCracken GH Jr. Pharmacology and efficacy of vancomycin for staphylococcal infections in children. Rev Infect Dis 1981; 3: S282-8
56. Burkhart KK, Metcalf S, Shurnas E, et al. Exchange transfusion and multidose activated charcoal following vancomycin overdose. J Toxicol Clin Toxicol 1992; 30: 285-94
57. de Hoog M, van Zanten BA, Hop WC, et al. Newborn hearing screening: tobramycin and vancomycin are not risk factors for hearing loss. J Pediatr 2003; 142: 41-6
58. Wysocki M, Delatour F, Faurisson F, et al. Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: Prospective multicenter randomized study. Antimicrob Agents Chemother 2009; 53: 1863-7
59. Pea F, Furlanut M, Negri C, et al. Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients. Antimicrob Agents Chemother 2001; 45: 2460-7
60. Cataldo MA, Tacconelli E, Grilli E, et al. Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. J Antimicrob Chemother 2012; 67: 17-24
61. Plan O, Cambonie G, Barbotte E, et al. Continuous-infusion vancomycin therapy for preterm neonates with suspected or documented Gram-positive infections: A new dosage schedule. Arch Dis Child Fetal Neonatal Ed 2008; 93: F418-21
62. Pawllotsky F, Thomas A, Kergueris MF, et al. Constant rate infusion of vancomycin in premature neonates: A new dosage schedule. Br J Clin Pharmacol 1998; 46: 163-7
63. Oudin C, Vialet R, Boulamery A, et al. Vancomycin prescription in neonates and young infants: toward a simplified dosage. Arch Dis Child Fetal Neonatal Ed 2011; 96: F365-70
64. ClinicalTrials. gov: A service of the U. S National Institute oh Health. Available from: https: //clinicaltrials. gov
65. Gwee A, Cranswick N, Metz D, et al. Neonatal vancomycin continuous infusions: still a confusion? Pediatr Infect Dis J 2013. [Epub ahead of print]
66. Ward RM, Allegaert K, de Groot R, van den Anker JN. Commentary: Continuous infusion of vancomycin in neonates: to use or not to use remains the question. Pediatr Infect Dis J 2014; 33: 606-7
67. Sherwin CM, Medlicott NJ, Reith DM, Broadbent RS. Intravenous drug delivery in neonates: lessons learnt. Arch Dis Child 2014; 99: 590-4
68. Isaacs D, Wilkinson AR, Moxon ER. Duration of antibiotic courses for neonates. Arch Dis Child 1987; 62: 727-8
69. Bizzaro JM, Gallagher PG. Antibiotic resistant organisms in the neonatal intensive care unit. Seminars Perinatol 2007; 31: 26-32
70. Stronati M, Borghesi A, Decembrino L, Bollani L. Antibiotics in neonatal intensive care units (NICUs). J Chemother 2007; 19: 52-5
71. Aguado-Lorenzo V, Weeks K, Tunstell P, et al. Accuracy of the concentration of morphin infusions prepared for patients in a NICU. Arch Dis Child 2013; 98: 975-9
72. WHO. Marketing authorization of pharmaceutical products with special reference to multisource (generic) products: A manual for a drug regulatory authority. World Health Organization, Geneva, Switzerland. Available from: http: //apps. who. int/prequal/info-general/documents/ WHO-DMP-RGS-98-5-R. pdf
73. Jong GW. In vivo inferiority of generic product compared with branded vancomycin: A paradigm shift. Ther Drug Monit 2012; 34: 2-3
74. Louie A, Boyne MT, Patel W, et al. Pharmacodynamic evaluation of the activities of six parenteral vancomycin products available in the United States. AAC 2015; 59: 622-32
75. Raverdy V, Ampe E, Hecq JD, Tulkens PMJ. Stability and compatibility of vancomycin for administration by continuous infusion. Antimicrob Chemother 2013; 68: 1179-82
76. Berti AD, Hutson PR, Schulz LT, et al. Compatibility of cefepime and vancomycin during simulated Y-site administration of prolonged infusion. Am J Health Syst Pharm 2015; 72: 390-5
77. Pritts D, Hancock D. Incompatibility of ceftriaxone with vancomycin. Am J Hosp Pharm 1991; 48: 77
78. The IV compatibility table IV. Available from: www. nursingconsult. com
79. Ringenberg T, Robinson C, Meyers R. Achievement of therapeutic vancomycin trough serum concentration with empirical dosing in neonatal intensive care unit patients. Pediatr Infect Dis J 2015; Epub anead of print
80. Patel MP, Pai KA, Rodvold B, et al. Vancomycin: we can't get there from here. Clin Infect Dis 2011; 52: 969-74
81. Frymoyer A, Hersh AL, El-Komy MH, et al. Association between vancomycin trough concentrations and area under the concentration-time curve inneonates. Antimicrob Agents Chemother 2014; 58: 6454-61
82. Pai MP, Neely M, Rodvold KA, Lodise TP. Innovative approaches to optimizing the delivery of vancomycin in individual patients. Adv Drug Deliv Rev 2014; 20: 50-7
83. Gross JR, Kaplan SL, Kramer WG, Mason EO Jr. Vancomycin pharmacokinetics in premature infants. Pediatr Pharmacol (New York) 1985; 5: 17-22
84. Naqvi SH, Keenan WJ, Reichley RM, Fortune KP. Vancomycin pharmacokinetics in small, seriously ill infants. Am J Dis Child 1986; 140: 107-10
85. Spivey JM, Gal P. Vancomycin pharmacokinetics in neonates. Am J Dis Child 1986; 140: 859
86. James A, Koren G, Milliken J, et al. Vancomycin pharmacokinetics and dose recommendations for preterm infants. Antimicrob Agents Chemother 1987; 31: 52-4
87. Reed MD, Kliegman RM, Weiner JS, et al. The clinical pharmacology of vancomycin in seriously ill preterm infants. Pediatr Res 1987; 22: 360-3
88. Lisby-Sutch SM, Nahata MC. Dosage guidelines for the use of vancomycin based on its pharmacokinetics in infants. Eur J Clin Pharmacol 1988; 35: 637-42
89. Kildoo CW, Lin LM, Gabriel MH, et al. Vancomycin pharmacokinetics in infants: relationship to postconceptional age and serum creatinine. Dev Pharmacol Ther 1989; 14: 77-83
90. Leonard MB, Koren G, Stevenson DK, Prober CG. Vancomycin pharmacokinetics in very low birth weight neonates. Pediatr Infect Dis J 1989; 8: 282-6
91. Jarrett RV, Marinkovich GA, Gayle EL, Bass JW. Individualized pharmacokinetic profiles to compute vancomycin dosage and dosing interval in preterm infants. Pediatr Infect Dis J 1993; 12: 156-7
92. Asbury WH, Darsey EH, Rose WB, et al. Vancomycin pharmacokinetics in neonates and infants: A retrospective evaluation. Ann Pharmacother 1993; 27: 490-6
93. McDougal A, Ling EW, Levine M. Vancomycin pharmacokinetics and dosing in premature neonates. Ther Drug Monit 1995; 17: 319-26
94. Amaker RD, DiPiro JT, Bhatia J. Pharmacokinetics of vancomycin in critically ill infants undergoing extracorporeal membrane oxygenation. Antimicrob Agents Chemother 1996; 40: 1139-42
95. Burstein AH, Gal P, Forrest A. Evaluation of a sparse sampling strategy for determining vancomycin pharmacokinetics in preterm neonates: Application of optimal sampling theory. Ann Pharmacother 1997; 31: 980-3
96. Buck ML. Vancomycin pharmacokinetics in neonates receiving extracorporeal membrane oxygenation. Pharmacotherapy 1998; 18: 1082-6
97. Fofah OO, Karmen A, Piscitelli J, Brion LP. Failure of prediction of peak serum vancomycin concentrations from trough values in neonates. Pediatr Infect Dis J 1999; 18: 299-301
98. Frattarelli DA, Ergun H, Lulic-Botica M, et al. Vancomycin elimination in human infants with intrauterine growth retardation. Pediatr Infect Dis J 2005; 24: 979-83
99. Machado JK, Feferbaum R, Kobayashi CE, et al. Vancomycin pharmacokinetics in preterm infants. Clinics (Sao Paulo) 2007; 62: 405-10
100. Seay RE, Brundage RC, Jensen PD, et al. Population pharmacokinetics of vancomycin in neonates. Clin Pharmacol Ther 1994; 56: 169-75
101. de Hoog M, Schoemaker RC, Mouton JW, van den Anker JN. Vancomycin population pharmacokinetics in neonates. Clin Pharmacol Ther 2000; 67: 360-7
102. Mulla H, Pooboni S. Population pharmacokinetics of vancomycin in patients receiving extracorporeal membrane oxygenation. Br J Clin Pharmacol 2005; 60: 265-75
103. Anderson BJ, Allegaert K, Van den Anker JN, et al. Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. Br J Clin Pharmacol 2007; 63: 75-84
104. Mehrotra N, Tang L, Phelps SJ, Meibohm B. Evaluation of vancomycin dosing regimens in preterm and term neonates using Monte Carlo simulations. Pharmacotherapy 2012; 32: 408-19
105. Zhao W, Lopez E, Biran V, et al. Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring. Arch Dis Child 2013; 98: 449-53
106. Patel AD, Anand D, Lucas C, Thomson AH. Continuous infusion of vancomycin in neonates-PostScript/letters. Arch Dis Child 2013; 98: 478-9
107. Pacifici GM, Allegeart K. Clinical pharmacokinetics of vancomycin in the neonate: A review. Clinics 2012; 67: 831-7